TD-HY196026

Onartuzumab(TD-HY196026) is a research-grade recombinant antibody targetingTyrosine-protein kinase Met. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

Fab-G1-kappa-[Fc-G1]

Monoclonal

Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P08581

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

tMAb, OA-5DMe5, PRO143966, 1133766-06-9

Davutamig (REGN-5093) is a human immunoglobulin G4-kappa, anti-MET monoclonal antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic.• MET-dependent solid tumours - molecular diagnosis and targeted therapy., PMID:32514147• ABBV-399, a c-Met Antibody-Drug Conjugate that Targets BothMET-Amplified and c-Met-Overexpressing Tumors, Irrespective ofMETPathway Dependence., PMID:27573171• Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis., PMID:34848680• The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance., PMID:30786811• The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions., PMID:26822708• MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas., PMID:34667077• Targeting HGF/c-MET Axis in Pancreatic Cancer., PMID:33271944• Targeting the hepatocyte growth factor/Met pathway in cancer., PMID:28673936• Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases., PMID:30658428• Hepatocyte growth factor in physiology and infectious diseases., PMID:28094206

SEC-HPLC detection for Research Grade Onartuzumab.　　|　SDS-PAGE for Research Grade Onartuzumab.

For research use only. Not suitable for clinical or therapeutic use.